Early Treatment Access and Palliative Care Integration for Patients with ES-SCLC

Dr. Sands argues that successful second-line agents should move earlier in treatment sequencing, citing precedent from other oncology fields. With only 40% to 50% of patients with ES-SCLC receiving second-line therapy due to rapid disease progression, declining functional status, or brain metastases, moving effective agents like tarlatamab earlier addresses this attrition problem.

He emphasizes that patients with SCLC are frequently undertreated, sharing examples of patients told hospice was their only option who subsequently achieved over a year of good quality life with tarlatamab. He advocates against restricting treatment access based solely on clinical trial eligibility criteria.

Dr. Shields highlights early palliative care integration, calling it "supportive oncology" to avoid implications of comfort-focused care alone. She integrates this support at diagnosis for all patients with SCLC, emphasizing the importance of alignment between oncology and palliative care teams to avoid conflicting messages about treatment goals and prognosis.

Dr. Sands describes scenarios where patients hospitalized for treatable complications like pneumonia face premature hospice discussions, contrasting this with how patients with heart failure receive disease-specific management rather than immediate goals-of-care conversations. He advocates for balanced communication presenting both best-case and worst-case scenarios, noting patients sometimes only hear worst-case projections online, while excellent long-term outcomes exist for some patients now exceeding 7 years from diagnosis.